Have you recently suffered from a Heart Attack or Stroke?

A Clinical Research Study may be an option for you!

Acute Coronary Syndrome (ACS) is an umbrella term that encompasses situations where the blood supplied to the heart muscle is suddenly blocked. This could cause heart attack, strokes or, angina (heart pain). 

We’re seeking participants for a research study to evaluate an experimental drug that may help reduce early recurrent cardiovascular events in heart attack survivors. 

You may be eligible to participate if you: 

  • Are at least 18 years or older
  • Have been hospitalized due to a heart attack 
  • Have blockage or plaque in your arteries
  • Are taking medications for your diabetes

Revival Research Institute is one of the 1000 sites that is working in collaboration with the sponsor to conduct this groundbreaking research study. We’re working to evaluate how a potential acute coronary syndrome treatment may be able to help reduce the risk of life-threatening heart-related complications, having another heart attack or, stroke after suffering through a recent heart attack.

*To participate in the research study, simply fill the form and someone from the research staff will get back to you shortly with a phone call. Your medical history will be collected by the research personnel. However, your information will not be disclosed to anyone outside of the organization, as stated in our Privacy Policy.

**Participating in the research study is free of cost to you and your insurance. You will not be charged in any capacity and will instead be provided with a stipend for every visit you make to the site, should you decide to participate in the study and if you qualify.

Please provide YOUR contact information only.
Acute Coronary Syndrome study

About the ACS Study

Revival Research Institute is collaborating with a sponsor on a phase 3 global mega trial with 17,000 patients across 1000 sites in roughly 50 countries. The study is looking at the effects of an experimental drug’s short-term intravenous infusion on cardiovascular events in high-risk patients during the critical 90-day period after a heart attack and if it might work as a potential acute coronary syndrome treatment. You may be eligible to participate in the study if you meet the inclusion criteria.

Screening, active treatment, and follow-up are the three phases of the study. For 4 weeks, the study drug will be administered via IV infusion once a week. Adverse effects will be monitored until the study is completed. If you decide to participate, once you are eligible, you will be monitored for the occurrence of major adverse cardiovascular events for 365 days. The study will last approximately 50 months in total.

*The study drug and study-related care is free of charge for volunteers who are eligible for the study. If you qualify, you will receive a call from someone on our research staff. You may be asked to share your personal information regarding your complete medical history, overall health, and any medication you take.

*All volunteers who may be eligible for the research study will receive the study drug and study-related care, free of cost. And you may be compensated for your time and travel. No insurance is required to participate.

Get Started: What to Expect?

If you qualify and decide to take part in the ACS study, you will first need to sign the Informed Consent Form. The study team will walk you through the process and discuss in detail your participation in the research study. It is entirely your decision whether or not you decide to take part in the research study. We encourage all participants to ask as many questions as they’d like about the clinical trial.

Once you sign the consent form and meet all the study requirements, you will be assigned to one of two study groups by random chance. Every participant has an equal chance (50%) of being assigned to either one of the study groups. One of the study groups will receive the placebo (medication without the active ingredient of the study drug) and the other group will receive the experimental drug. The study team will not know which medication you receive as this is a double-blind research study. However, your study doctor can learn which you have been assigned to in case there is an emergency.

The study medication and the placebo are both given by a series of intravenous infusions (sometimes known as a ‘drip’) to all participants. This means that the medication will be given slowly through a needle into a vein in your arm.

*Participation in the research study is completely voluntary. Every participant has the right to withdraw from the study at any time in the duration of the study.

Condition

Acute Coronary Syndrome (ACS)

Length of Study Treatment

1 month & 8 months follow-up

Number of Study Visits

8-9 visits onsite & 2 phone visits

About Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trials

Acute coronary syndrome (ACS) is a collection of signs and symptoms caused by a decrease in blood flow in the coronary arteries, which causes part of the heart muscle to stop working and results in a heart attack.

Symptoms

Acute coronary syndrome symptoms typically appear suddenly, sometimes without warning. Severe chest pain or discomfort characterizes ACS. It’s a medical emergency that necessitates immediate diagnosis and treatment. Other signs and symptoms include:

  • Back, jaw, neck, or stomach pain in one or both arms
  • Breathing problems
  • Lightheadedness or dizziness
  • Indigestion
  • Nausea or vomiting
  • Sweating

Am I At Risk?

People should be aware of various risk factors linked with acute coronary syndrome. Some of the risk factors include being over the age of 45, leaving with cholesterol or blood pressure problems, smoking, insufficient physical activity, obesity, diabetes and, having a family history of the condition.

Prevention

In some cases, acute coronary syndrome can be avoided. The acute coronary syndrome is caused by heart disease, but those who do not have it can protect themselves by eating a heart-healthy diet, quitting smoking, drinking alcohol in moderation, being active, and maintaining a healthy weight.

Frequently Asked Questions

What is Acute Coronary Syndrome?

Acute coronary syndrome (ACS) is a group of symptoms and signs caused by a blockage in the coronary arteries. Chest discomfort, dyspnea, and electrocardiographic irregularities are common signs and symptoms. A blockage of the coronary artery due to cholesterol-rich plaque and thrombus is the most prevalent cause of the acute coronary syndrome.

Why is the ACS Clinical Trial being done?

We know that a person who has recently suffered from a heart attack is at a higher risk of suffering from some heart-related complication, another heart attack or strokes, in the first few months of suffering from one. Because the chance of suffering from some heart-related complication is very high, researchers and scientists are looking for new ways to provide extra protection during that time. The ACS clinical trial is studying an experimental medication that may be able to provide this layer of extra protection during this critical time for you.

How to prevent repeat attacks?

People who’ve suffered from heart attacks are at higher risk for repeat attacks. However, participating in clinical trials can be a potential treatment option for all those who want to live a normal life after ACS.

Is the incidence the same for males and females?

Men are more prone than women to develop coronary artery disease and have heart attacks earlier in life. After menopause, a woman’s risk of heart attack rises.

What is a double-blind research study?

The Acute Coronary Syndrome clinical trial is an example of a double-blind study. This means that there are two groups assigned to the research study. One will receive the placebo (medication without the active ingredient) and the other will receive the study drug. Neither you nor the research staff including the study doctor will not know which group you’ve been assigned to. Every participant has an equal chance (50%) of being assigned to either one of the two groups.